Gabriela Kaiserberger

Director

πŸ“ SpainπŸ”„ Updated September 2026πŸ’Ό 5 investmentsπŸ“… 8 years investingπŸ—“ Last invested Jan 2022
Angel investor🌍 Spain
5
Total investments
2
Early stage
1
Mid stage
0
Late stage
8y
Years active

Portfolio

5 investments Β· sorted by recency
All investments
Early stage
Mid stage
Late stage
Investor
2022
TECO Global Mobility is a European Mobility-as-a-Service (MaaS) company that provides Sustainable Private e-Scooter Solutions for Hotels
Investor
2021
Welcome to Galaxy Genomics (G2) - a trailblazer in deterministic protein, peptide, and enzyme engineering. Leveraging our cutting-edge mathematical and computational algorithms, we provide transformative solutions for pharmaceutical, chemical, cosmetic, and food industries globally. For pharmaceuticals and biotech, we supercharge drug discovery and personalized medicine. By precisely manipulating proteins and peptides, we boost the development of targeted therapeutics, minimizing the uncertainty common in drug discovery. In the chemical realm, we optimize processes through tailored enzyme engineering. Our technology fosters efficient reactions, reduces waste, and enhances sustainable practices. Within cosmetics and beauty, our protein and peptide engineering plays a pivotal role in formulating safer, superior products. Our unique ability to design bioactive ingredients reduces side effects and speeds up product development. In the food sector, our deterministic enzyme engineering aids in creating healthier, eco-friendly food products. Our capabilities allow companies to improve nutritional content, lower allergens, and foster sustainable production. At G2, we believe in unleashing the power of proteins, peptides, and enzymes to spark innovation across diverse industries. As we continue to grow globally, we remain committed to empowering businesses with our unique capabilities. Explore the potential of deterministic bioengineering with G2, and together, lets foster innovation and sustainability.
early stageBiotechnology
Board Member
2021
A2 Fortune (A2F) is an American private holding company. Our strategy is to invest in building thriving and resilient businesses that have the potential to generate better returns and economic growth that benefits employees, communities, and shareholders. We invest in growth-oriented businesses. We modernize companies by implementing strategic digital transformation initiatives to improve operational processes that drive value. We are constantly looking for opportunities where we can add value using our specialized knowledge and experience.
Investor
Mar 2018
At Hyperloop One, we’re turning science fiction into reality as we prepare to launch a new form of autonomous, on-demand transport that is faster, safer, cost-efficient and more sustainable than existing modes.
Experience Β· 5 entries
All (5)
Investments (5)
Board (1)
2022
Investor
2022
TECO Global Mobility is a European Mobility-as-a-Service (MaaS) company that provides Sustainable Private e-Scooter Solutions for Hotels
2021
Investor
2021
Welcome to Galaxy Genomics (G2) - a trailblazer in deterministic protein, peptide, and enzyme engineering. Leveraging our cutting-edge mathematical and computational algorithms, we provide transformative solutions for pharmaceutical, chemical, cosmetic, and food industries globally. For pharmaceuticals and biotech, we supercharge drug discovery and personalized medicine. By precisely manipulating proteins and peptides, we boost the development of targeted therapeutics, minimizing the uncertainty common in drug discovery. In the chemical realm, we optimize processes through tailored enzyme engineering. Our technology fosters efficient reactions, reduces waste, and enhances sustainable practices. Within cosmetics and beauty, our protein and peptide engineering plays a pivotal role in formulating safer, superior products. Our unique ability to design bioactive ingredients reduces side effects and speeds up product development. In the food sector, our deterministic enzyme engineering aids in creating healthier, eco-friendly food products. Our capabilities allow companies to improve nutritional content, lower allergens, and foster sustainable production. At G2, we believe in unleashing the power of proteins, peptides, and enzymes to spark innovation across diverse industries. As we continue to grow globally, we remain committed to empowering businesses with our unique capabilities. Explore the potential of deterministic bioengineering with G2, and together, lets foster innovation and sustainability.
early stageBiotechnology
Board Member
2021
A2 Fortune (A2F) is an American private holding company. Our strategy is to invest in building thriving and resilient businesses that have the potential to generate better returns and economic growth that benefits employees, communities, and shareholders. We invest in growth-oriented businesses. We modernize companies by implementing strategic digital transformation initiatives to improve operational processes that drive value. We are constantly looking for opportunities where we can add value using our specialized knowledge and experience.
2018
Investor
Mar 2018
At Hyperloop One, we’re turning science fiction into reality as we prepare to launch a new form of autonomous, on-demand transport that is faster, safer, cost-efficient and more sustainable than existing modes.
Investment activity
2018–2022 Β· 5 investments
201822021220221
Recent (last 2 years)Earlier